

Kansas Health Policy Authority (KHPA) Medical Programs

Program Assessment for State Fiscal Year 2009

Presented October 2009

KHPA Medical Programs SFY2009 Program Assessment

Program Summary	3
Yearly Totals	3
Monthly Totals	3
Monthly Trend Summary	4
Drug Classification Reporting	6
Therapeutic Class Reporting	7
Top Therapeutic Classes by Total Number of Claims	7
Top Therapeutic Classes by Total Cost of Claims	8
Trend Summary Analysis	9
Atypical Antipsychotics	9
Anticonvulsants	10
Antidepressants	11
Generic Ingredient Level Reporting	12
Top Generic Ingredients by Total Number of Claims	12
Top Generic Ingredients by Total Cost of Claims	13
Specific Drug Level Reporting	14
Top Drugs by Total Number of Claims	14
Top Drugs by Total Cost of Claims	15
Past Years' Comparative	17
Conclusion	17

Yearly Totals

During the State Fiscal Year (SFY) of 2009 (July 1, 2008 through June 30, 2009), the Kansas Health Policy Authority (KHPA) Medical Programs paid over \$175 million (rebates not included) on approximately two million prescriptions for fee-for-service (FFS) beneficiaries. This is a nearly \$16 million increase in prescription expenditures from SFY 2008, when KHPA Medical Programs paid nearly \$159 million on prescription claims.

KHPA Medical Programs averaged 142,493 members

(beneficiaries) per month. Beneficiary eligibility types include not only Title 19 (TXIX), but also Medically Needy, MediKan, the AIDS Drug Assistance Program (ADAP), and Presumptive Eligibility 19. KHPA Medical Programs covers other eligibility types through its Managed Care choices (not included in this report).

12 Month Assessment 7/01/08 - 06/30/09 Period Covered: Rx Claims Cost: \$175,085,301.76 2,037,193 Total Members: 270,497 Total Users: 116,220 47,414 Avg User Per Month: Avg Cost Per User Over Period: \$1,506.50 Avg Cost Per User Per Month: \$307.73 Avg Cost Per Claim: \$85.94

Table 1: Yearly Program Summary

Members vs. Users

Member: a beneficiary covered under KHPA Medical Programs, excluding Managed Care choices.

User: a member who received at least one prescription.

While KHPA Medical Programs averages 142,493 members per month, the average user per month was much lower at 47,414 ("user" is defined as a member who received at least one prescription). By using this distinction, a better picture of what KHPA Medical Programs pays per user for drug expenditures is seen—a cost that is typically much higher than per member cost.

For SFY 2009, KHPA Medical Programs paid an average per member per month cost of \$102.44, and an average per user per month cost of \$307.73. The average cost per claim for SFY 2009 was \$85.94.

Table 1 contains a yearly program summary.

Monthly Totals

The number of members in the FFS population increased from July 2008 to June 2009—most likely due to the recession and an increase in the number of persons eligible for assistance. Along with the increase in members there was an increase in users and the number of prescription claims. Monthly prescription costs remained nearly unchanged from July 2008 to June 2009; however, several spikes were experienced in the winter months. This was possibly due to an increase in use of acute medications during those months.

The average cost per claim decreased from \$87.02 in July 2008 to \$80.65 in June 2009. This was possibly due to the increase in the generic availability of several major drug classes, including atypical antipsychotics and anticonvulsants, during SFY 2009.

Table 2 contains a monthly synopsis of claim expenditures along with the number of members, users, amount KHPA Medical Programs paid per member per month, per user per month, and per claim per month.

Figures 1-5 trend the monthly totals, including Number of Prescriptions Per Month, Monthly Claims Cost, Cost Per Member Per Month, Cost Per User Per Month, and Average Cost Per Prescription Per Month.





Monthly Drug Expenditures

Table 2: Monthly Program Summary

					Cost Per	Cost Per	
Period					Member Per	User Per	Avgerage
Covered	Members	Users	# Rx	Rx Claims Cost	Month	Month	Cost/Claim
Jul-08	138,571	45,086	163,963	\$14,267,502.46	\$102.96	\$316.45	\$87.02
Aug-08	140,216	45,809	163,380	\$14,536,965.45	\$103.68	\$317.34	\$88.98
Sep-08	141,890	47,462	169,496	\$14,857,879.52	\$104.71	\$313.05	\$87.66
Oct-08	142,219	48,556	177,489	\$15,560,677.35	\$109.41	\$320.47	\$87.67
Nov-08	139,729	46,110	157,092	\$13,752,978.11	\$98.43	\$298.26	\$87.55
Dec-08	140,500	47,894	178,294	\$15,998,788.17	\$113.87	\$334.05	\$89.73
Jan-09	142,319	48,416	173,054	\$15,120,460.10	\$106.24	\$312.30	\$87.37
Feb-09	142,871	48,094	164,186	\$13,912,555.36	\$97.38	\$289.28	\$84.74
Mar-09	145,336	48,976	177,546	\$15,146,501.87	\$104.22	\$309.26	\$85.31
Apr-09	145,982	48,835	174,882	\$14,469,999.37	\$99.12	\$296.30	\$82.74
May-09	145,144	47,308	167,368	\$13,714,264.26	\$94.49	\$289.89	\$81.94
Jun-09	145,147	46,420	170,443	\$13,746,729.74	\$94.71	\$296.14	\$80.65

Figure 1: Number of Prescriptions per Month







Monthly Drug Expenditures

Figure 3: Monthly Cost per Member




Figure 4: Monthly Cost per User





Figure 5: Monthly Cost per Prescription





Drug Classification Reporting

It is important to not only report drug expenditures according to beneficiary lives, claim numbers, paid amounts, and so forth, but to also review the drug expenditures by varying degrees of drug classifications—from therapeutic classes to specific ingredients.

Reporting the drug classifications by total cost of claims and total number of claims will show where the largest drug expenditures are for the KHPA Medical Programs, as well as identifying the most commonly-prescribed medications. This can help identify where there is potential for cost savings or clinically-significant interventions.

Therapeutic Classes

The therapeutic classes are reported by the top 15 classes based on total number of claims, along with the top 15 classes based on the total cost of claims. Therapeutic class reporting is based on American Hospital Formulary Service (AHFS) Pharmacologic – Therapeutic Classification third hierarchy level.

It is important to report the top therapeutic classes based on both number of claims as well as the total cost of claims to see where therapeutic classes overlap, and which classes would be lost if these were only reported using one method. Examples of drug classes that would potentially be lost if only reported by total number of claims would be the hemostatics and antiretrovirals. Both represent a high expenditure for KHPA Medical Programs though they represent a small percentage of total claims. This is due to the high cost of these agents. One example is Alphanate, a hemostatic agent, which in SFY2009 cost anywhere from \$500 to \$152,000 per claim depending on a member's specific needs.

Table 3 contains the top 15 therapeutic classes based on the total number of claims, and **Table 4** reports the top 15 therapeutic classes based on the total cost of claims.

Figure 6 shows the distribution of the top 10 therapeutic classes based on the total number of claims, and **Figure 7** shows the distribution of the top 10 therapeutic classes based on the total cost of claims.

AHFS Pharmacologic—Therapeutic Classification Hierarchy Example						
8:00—Anti-infective Agents						
8:12—Antibacterials						
8:12.16—Penicillins*						
8:12.16.08—Aminopenicillins						

^{*}Therapuetic Classes are reported at this level.




Therapeutic Class Reporting

Table 3: Top 15 Therapeutic Classes By Total Number of Claims

				Average		% Total
AHFS Therapeutic Class	# Rx	R	x Claims Cost	Cost/Claim		Claims
Antidepressants	153,776	\$	7,644,717.19	\$	49.71	7.55%
Opiate Agonists	136,828	\$	6,440,789.81	\$	47.07	6.72%
Antipsychotic Agents	135,636	\$	41,013,018.60	\$	302.38	6.66%
Anticonvulsants, Misc.	110,293	\$	14,643,432.83	\$	132.77	5.41%
Benzodiazepines (Anxiolytic, Sed/Hyp)	93,518	\$	1,167,651.04	\$	12.49	4.59%
Nonsteroidal Anti-Inflammatory Agents	67,321	\$	1,062,583.95	\$	15.78	3.30%
Second Generation Antihistamines	66,099	\$	1,048,979.99	\$	15.87	3.24%
Beta-Adrenergic Agonists	65,168	\$	5,036,551.00	\$	77.29	3.20%
Proton-Pump Inhibitors	50,577	\$	6,790,162.72	\$	134.25	2.48%
Benzodiazepines (Anticonvulsants)	44,848	\$	239,855.07	\$	5.35	2.20%
Beta-Adrenergic Blocking Agents	39,187	\$	477,251.43	\$	12.18	1.92%
Anorex, Respir, Cerebral Stim, Misc	38,223	\$	4,620,177.12	\$	120.87	1.88%
Angiotensin-Converting Enzyme Inhibitor	38,141	\$	225,378.20	\$	5.91	1.87%
HMG-CoA Reductase Inhibitors	37,861	\$	2,223,457.94	\$	58.73	1.86%
Penicillins	35,824	\$	595,104.01	\$	16.61	1.76%
Total Top 15	1,113,300	\$	93,229,110.90	\$	83.74	54.65%

Figure 6: Top 10 Therapeutic Classes by Total Number of Claims

Top 10 Therapeutic Classes Based on Total Claims






Therapeutic Class Reporting

Table 4: Top 15 Therapeutic Classes By Total Cost of Claims

			Average	% Total
AHFS Therapeutic Class	# Rx	Rx Claims Cost	Cost/Claim	Claims Cost
Antipsychotic Agents	135,636	\$ 41,013,018.60	\$ 302.38	23.42%
Anticonvulsants, Misc.	110,293	\$ 14,643,432.83	\$ 132.77	8.36%
Hemostatics	550	\$ 13,963,504.94	\$25,388.19	7.98%
Antiretrovirals	15,725	\$ 10,225,393.96	\$ 650.26	5.84%
Antidepressants	153,776	\$ 7,644,717.19	\$ 49.71	4.37%
Proton-Pump Inhibitors	50,577	\$ 6,790,162.72	\$ 134.25	3.88%
Opiate Agonists	136,828	\$ 6,440,789.81	\$ 47.07	3.68%
Beta-Adrenergic Agonists	65,168	\$ 5,036,551.00	\$ 77.29	2.88%
Anorex, Respir, Cerebral Stim, Misc	38,223	\$ 4,620,177.12	\$ 120.87	2.64%
Amphetamines	34,999	\$ 4,061,518.41	\$ 116.05	2.32%
Insulins	26,963	\$ 3,975,329.49	\$ 147.44	2.27%
Leukotriene Modifiers	24,174	\$ 2,497,469.15	\$ 103.31	1.43%
HMG-CoA Reductase Inhibitors	37,861	\$ 2,223,457.94	\$ 58.73	1.27%
Central Nervous System Agents, Misc	13,340	\$ 1,943,811.64	\$ 145.71	1.11%
Adrenals	31,454	\$ 1,935,147.75	\$ 61.52	1.11%
Total Top 15	875,567	\$127,014,482.55	\$ 145.07	72.54%

Figure 7: Top 10 Therapeutic Classes by Total Cost of Claims

Top 10 Therapeutic Classes Based on Total Claims Cost





Trend Summary Analysis


Of note, within the top 15 therapeutic classes by total cost of claims and total number of claims there are three drug classes that appear in the top five in both measures: antipsychotics, anticonvulsants, and antidepressants. For the past several years, these three drug classes have been, and continue to be, a large expenditure and are also some of the most commonly-prescribed drug classes.

Tables 5, 6, and **7** show the monthly percent change by number of users, number of prescriptions, and prescription claims cost for atypical antipsychotics, anticonvulsants, and antidepressants.

Figures 7, 8, and **9** show cost of claims compared to the number of claims per month for atypical antipsychotics, anticonvulsants, and antidepressants.

Period Covered	Users	% Change	# Rx	% Change	Rx Claims Cost	% Change
Jun-08	7,166		10,058		\$3,366,999.22	
Jul-08	7,317	2.11%	10,614	5.53%	\$3,517,466.04	4.47%
Aug-08	7,304	-0.18%	10,258	-3.35%	\$3,373,252.29	-4.10%
Sep-08	7,468	2.25%	10,526	2.61%	\$3,428,196.88	1.63%
Oct-08	7,674	2.76%	11,101	5.46%	\$3,706,295.42	8.11%
Nov-08	7,187	-6.35%	9,842	-11.34%	\$3,264,059.98	-11.93%
Dec-08	7,690	7.00%	11,315	14.97%	\$3,732,861.25	14.36%
Jan-09	7,592	-1.27%	10,712	-5.33% \$3,407,612.93		-8.71%
Feb-09	7,377	-2.83%	10,094	-5.77%	\$3,119,969.85	-8.44%
Mar-09	7,682	4.13%	10,903	8.01%	\$3,383,173.24	8.44%
Apr-09	7,633	-0.64%	10,707	-1.80%	\$3,312,163.13	-2.10%
May-09	7,482	-1.98%	10,348	-3.35%	\$3,230,949.52	-2.45%
Jun-09	7,550	0.91%	10,784	4.21%	\$3,337,477.43	3.30%

Figure 7: Atypical Antipsychotics Cost of Claims Compared to Number of Prescriptions






Trend Summary Analysis Anticonvulsants

Table 6: Anticonvulsants Trend Summary Analysis

Period Covered	Recipients	% Change	# Rx's	% Change	Rx Claims Cost	% Change
Jun-08	6,318		8,969		\$1,497,009.41	
Jul-08	6,487	2.67%	9,283	3.50%	\$1,515,742.38	1.25%
Aug-08	6,401	-1.33%	9,110	-1.86%	\$1,424,965.35	-5.99%
Sep-08	6,499	1.53%	9,194	0.92%	\$1,425,938.70	0.07%
Oct-08	6,594	1.46%	9,469	2.99%	\$1,469,558.03	3.06%
Nov-08	6,247	-5.26%	8,596	-9.22%	\$1,268,981.91	-13.65%
Dec-08	6,641	6.31%	9,663	12.41%	\$1,338,750.52	5.50%
Jan-09	6,666	0.38%	9,335	-3.39%	\$1,275,865.81	-4.70%
Feb-09	6,195	-7.07%	8,553	-8.38%	\$1,115,257.02	-12.59%
Mar-09	6,631	7.04%	9,504	11.12%	\$1,233,620.40	10.61%
Apr-09	6,535	-1.45%	9,227	-2.91%	\$1,066,368.07	-13.56%
May-09	6,404	-2.00%	9,036	-2.07%	\$895,852.90	-15.99%
Jun-09	6,515	1.73%	9,323	3.18%	\$612,531.74	-31.63%

Figure 8: Anticonvulsants Cost of Claims Compared to Number of Prescriptions






Trend Summary Analysis Antidepressants

Table 7: Antidepressants Trend Summary Analysis

Period Covered	Recipients	% Change	# Rx's	% Change	Rx Claims Cost	% Change
Jun-08	9,151		12,105		\$679,976.92	
Jul-08	9,383	2.54%	12,501	3.27%	\$704,469.70	3.60%
Aug-08	9,531	1.58%	12,539	0.30%	\$691,803.12	-1.80%
Sep-08	9,571	0.42%	12,645	0.85%	\$626,756.49	-9.40%
Oct-08	9,895	3.39%	13,194	4.34% \$650,425.39		3.78%
Nov-08	9,159	-7.44%	11,793	-10.62% \$579,655.27		-10.88%
Dec-08	9,899	8.08%	13,482	14.32%	\$663,380.13	
Jan-09	9,767	-1.33%	12,920	-4.17%	\$628,566.73	-5.25%
Feb-09	9,439	-3.36%	12,133	-6.09%	\$574,112.06	-8.66%
Mar-09	9,988	5.82%	13,282	9.47%	\$640,874.70	11.63%
Apr-09	9,976	-0.12%	13,225	-0.43%	\$626,064.01	-2.31%
May-09	9,753	-2.24%	12,792	-3.27%	\$619,762.38	-1.01%
Jun-09	9,933	1.85%	13,270	3.74%	\$638,847.21	3.08%

Figure 9: Antidepressants Cost of Claims Compared to Number of Prescriptions





Generic Ingredient Level Reporting

The next level of reporting is the generic ingredient level. This level is reported as the top 50 generic ingredients based on total number of claims and total cost of claims.

This level of reporting includes all claims classified under a generic name. One example of this is olanzapine. At the generic ingredient level all claims for Zyprexa, as well as claims for Zyprexa Zydis, would be reported under olanzapine.

Table 8 contains the top 50 generic ingredients by total number of claims, and **Table 9** contains the top 50 generic ingredients by total cost of claims.

Table 8: Top 25 Generic Ingredients By Total Number of Claims

Generic Name	AHFS Therapeutic Class	# Rx	Rx Claims Cost
Hydrocodone Bit/APAP	Opiate Agonists	63,282	\$ 701,910.83
Loratadine	Second Generation Antihistamines	45,700	\$ 435,763.46
Clonazepam	Benzodiazepines (Anticonvulsants)	44,848	\$ 239,855.07
Lansoprazole	Proton-Pump Inhibitors	37,859	\$ 5,941,737.13
Alprazolam	Benzodiazepines (Anxiolytic, Sed/Hyp)	37,741	\$ 181,248.43
Albuterol Sulfate	Beta-Adrenergic Agonists	36,241	\$ 1,050,974.07
Quetiapine Fumarate	Antipsychotic Agents	35,074	\$ 10,383,403.12
Lorazepam	Benzodiazepines (Anxiolytic, Sed/Hyp)	31,502	\$ 279,564.34
Risperidone	Antipsychotic Agents	29,359	\$ 3,757,120.11
Levothyroxine Sodium	Thyroid Agents	27,798	\$ 224,610.33
Divalproex Sodium	Anticonvulsants, Misc	26,838	\$ 3,272,412.22
Aspirin	Nonsteroidal Anti-Inflammatory Agents	26,653	\$ 95,862.97
Methylphenidate HCl	Anorex, Respir, Cerebral Stim, Misc	26,287	\$ 2,870,138.77
Lisinopril	Angiotensin-Converting Enzyme Inhibitors	25,774	\$ 140,055.14
Aripiprazole	Antipsychotic Agents	24,851	\$ 11,978,638.20
Amoxicillin Trihydrate	Penicillins	24,700	\$ 167,333.69
Montelukast Sodium	Leukotriene Modifiers	23,774	\$ 2,462,822.56
Azithromycin	Macrolides	23,342	\$ 527,493.94
Sertraline HCl	Antidepressants	22,184	\$ 298,282.30
Clonidine HCl	Central Alpha-Agonists	21,717	\$ 348,232.27
Trazodone HCl	Antidepressants	21,367	\$ 143,734.08
Metfromin HCl	Biguanides	20,602	\$ 99,623.72
Escitalopram Oxalate	Antidepressants	19,863	\$ 1,853,325.61
Furosemide	Loop Diuretics	19,080	\$ 80,471.38
Simvastatin	HMG-CoA Reductase Inhibitors	18,111	\$ 74,862.61
Total Top 25		734,547	\$ 47,609,476.35



Generic Ingredient Level Reporting

Table 9: Top 25 Generic Ingredients By Total Cost of Claims

Generic Name	AHFS Therapeutic Class	# Rx	Rx Claims Cost
Ariprazole	Antipsychotic Agents	24,851	\$ 11,978,638.20
Quetiapine Fumarate	Antipsychotic Agents	35,074	\$ 10,383,403.12
Lansoprazole	Proton-Pump Inhibitors	37,859	\$ 5,941,737.13
Olanzapine	Antipsychotic Agents	9,536	\$ 5,150,700.08
AHF,Human/VWF,Human	Hemostatics	91	\$ 4,857,678.79
Ziprasidone HCl	Antipsychotic Agents	12,730	\$ 4,044,024.78
Antihemoph. FVIII Plas/Alb Free	Hemostatics	159	\$ 3,936,618.47
Risperidone	Antipsychotic Agents	29,359	\$ 3,757,120.11
Antihemophilic Factor, Hum Rec	Hemostatics	182	\$ 3,428,323.16
Divalproex Sodium	Anticonvulsants, Misc	26,838	\$ 3,272,412.22
Oxycodone HCl	Opiate Agonists	12,746	\$ 3,026,042.93
Topiramate	Anticonvulsants, Misc	11,619	\$ 2,971,197.68
Methylphenidate HCl	Anorex, Respir, Cerebral Stim, Misc	26,287	\$ 2,870,138.77
Lamotrigine	Anticonvulsants, Misc	16,209	\$ 2,862,849.44
Efavirenz/Emtricitab/Tenofovir	Antiretrovirals	2,129	\$ 2,618,069.29
Paliperidone	Antipsychotic Agents	6,721	\$ 2,572,798.03
Montelukast Sodium	Leukotriene Modifiers	23,774	\$ 2,462,822.56
Fluticasone/Salmeterol	Beta-Adrenergic Agonists	12,049	\$ 2,380,006.13
Risperidone Microspheres	Antipsychotic Agents	3,417	\$ 2,358,247.02
Amphet Asp/Amphet/D-Amphet	Amphetamines	16,519	\$ 2,046,914.54
Lisdexamfetamine Dimesylate	Amphetamines	16,192	\$ 1,895,065.81
Duloxetine HCl	Antidepressants	11,896	\$ 1,877,579.88
Escitalopram Oxalate	Antidepressants	19,863	\$ 1,853,325.61
Emtricitabine/Tenofovir	Antiretrovirals	2,325	\$ 1,798,723.56
Atorvastatin Calcium	HMG-CoA Reductase Inhibitors	16,073	\$ 1,762,310.82
Total Top 25		374,498	\$ 92,106,748.13



Drug Level Reporting

The final level of reporting is the specific drug level, which is reported using the top 25 drugs based on number of claims, and the top 25 drugs based on total cost of claims.

This level is more specific than the generic ingredient level since it reports on one agent. An example of this is Risperdal and Risperdal Consta. At the generic ingredient level, these agents are reported under risperidone; whereas here they are reported separately.

Again, it is important to review this level both by number of claims and total cost of claims to see the drugs that are most costly as well as those drugs that are most commonly-prescribed. Several agents would be lost if these were reported using only one method. For example, several benzodiazepines appear on the top 25 drugs based on number of claims and, while these drugs are frequently prescribed, they represent a smaller cost to KHPA Medical Programs compared to other agents.

Table 10: Top 25 Drugs By Total Number of Claims

					Α	verage	% Total
Drug	AHFS Therapeutic Class	# Rx	R	x Claims Cost	Co	st/Claim	Claims
Hydrocodone/APAP	Opiate Agonists	63,192	\$	698,203.50		11.05	3.10%
Clonazepam	Benzos (Anticonvulsants)	44,726	\$	234,872.39	\$	5.25	2.20%
Loratadine	2 nd Generation Antihistamines	44,441	\$	422,379.75	\$	9.50	2.18%
Prevacid	Proton-Pump Inhibitors	37,859	\$	5,941,737.13	\$	156.94	1.86%
Alprazolam	Benzos (Anxiolytic, Sed/Hyp)	37,725	\$	181,167.48	\$	4.80	1.85%
Lorazepam	Benzos (Anxiolytic, Sed/Hyp)	31,048	\$	263,600.66	\$	8.49	1.52%
Seroquel	Antipsychotic Agents	30,533	\$	8,777,342.47	\$	287.47	1.50%
Lisinopril	ACE Inhibitors	25,774	\$	140,055.14	\$	5.43	1.27%
Risperidone	Antipsychotic Agents	25,452	\$	2,868,445.97	\$	112.70	1.25%
Abilify	Antipsychotic Agents	24,558	\$	11,825,786.95	\$	481.55	1.21%
Amoxicillin	Penicillins	24,212	\$	164,712.46	\$	6.80	1.19%
Singulair	Leukotriene Modifiers	23,774	\$	2,462,822.56	\$	103.59	1.17%
Azithromycin	Macrolides	23,203	\$	521,180.70	\$	22.46	1.14%
Levothyroxine	Thyroid Agents	23,202	\$	178,681.29	\$	7.70	1.14%
Sertraline	Antide pressants	22,017	\$	293,240.79	\$	13.32	1.08%
Trazodone	Antidepressants	21,367	\$	143,734.08	\$	6.73	1.05%
Clonidine	Central Alpha-Agonists	20,600	\$	138,274.10	\$	6.71	1.01%
Lexapro	Antide pressants	19,863	\$	1,853,325.61	\$	93.31	0.98%
Proair HFA	Beta-Adrenergic Agonists	19,798	\$	654,058.78	\$	33.04	0.97%
Metformin	Biguanides	19,168	\$	83,629.70	\$	4.36	0.94%
Furosemide	Loop Diuretics	19,066	\$	80,403.63	\$	4.22	0.94%
Simvastatin	HMG-CoA Reductase Inhibitors	18,086	\$	74,752.64	\$	4.13	0.89%
Concerta	Anor, Resp, Cerebral Stim, Misc	16,764	\$	2,161,432.19	\$	128.93	0.82%
Vyvanse	Amphetamines	16,192	\$	1,895,065.81	\$	117.04	0.79%
Lipitor	HMG-CoA Reductase Inhibitors	16,073	\$	1,762,310.82	\$	109.64	0.79%
Total Top 25		668,693	\$	43,821,216.60	\$	65.53	32.82%



Drug Level Reporting

Table 10 contains the top 25 drugs based on number of claims, reported by number of prescriptions, amount paid, amount paid per prescription, and percent of total claims, and **Table 11** contains the top 25 drugs based on total cost of claims.

Figure 10 shows the distribution of the top 10 drugs based on number of claims, and **Figure 11** shows the distribution of the top 10 drugs based on total cost of claims.

Table 11: Top 25 Drugs By Total Cost of Claims

				Average	% Total
Drug	AHFS Therapeutic Class	# Rx	Rx Claims Cost	Cost/Claim	Claims Cost
Abilify	Antipsychotic Agents	24,558	\$11,825,786.95	\$ 481.55	6.75%
Seroquel	Antipsychotic Agents	30,533	\$ 8,777,342.47	\$ 287.47	5.01%
Prevacid	Proton-Pump Inhibitors	37,859	\$ 5,941,737.13	\$ 156.94	3.39%
Alphanate	Hemostatics	80	\$ 4,817,258.56	\$60,215.73	2.75%
Zyprexa	Antipsychotic Agents	8,023	\$ 4,271,464.21	\$ 532.40	2.44%
Geodon	Antipsychotic Agents	12,758	\$ 4,045,365.11	\$ 317.08	2.31%
Risperidone	Antipsychotic Agents	25,452	\$ 2,868,445.97	\$ 112.70	1.64%
Topamax	Anticonvulsants, Misc	9,363	\$ 2,738,961.03	\$ 292.53	1.56%
Kogenate FS	Hemostatics	128	\$ 2,697,552.82	\$21,074.63	1.54%
Atripla	Antiretrovirals	2,129	\$ 2,618,069.29	\$ 1,229.72	1.50%
Invega	Antipsychotic Agents	6,721	\$ 2,572,798.03	\$ 382.80	1.47%
Singulair	Leukotriene Modifiers	23,774	\$ 2,462,822.56	\$ 103.59	1.41%
Risperdal Consta	Antipsychotic Agents	3,417	\$ 2,358,247.02	\$ 690.15	1.35%
Advair Diskus	Beta-Adrenergic Agonists	11,323	\$ 2,230,933.33	\$ 197.03	1.27%
Concerta	Anor, Resp, Cerebral Stim, Misc	16,764	\$ 2,161,432.19	\$ 128.93	1.23%
Lamotrigine	Anticonvulsants, Misc	12,852	\$ 2,113,805.45	\$ 164.47	1.21%
Oxycontin	Opiate Agonists	5,411	\$ 1,954,987.48	\$ 361.30	1.12%
Vyvnase	Amphetamines	16,192	\$ 1,895,065.81	\$ 117.04	1.08%
Cymbalta	Antidepressants	11,896	\$ 1,877,579.88	\$ 157.83	1.07%
Lexapro	Antidepressants	19,863	\$ 1,853,325.61	\$ 93.31	1.06%
Truvada	Antiretrovirals	2,325	\$ 1,798,723.56	\$ 773.64	1.03%
Lipitor	HMG-CoA Reductase Inhibitors	16,073	\$ 1,762,310.82	\$ 109.64	1.01%
Strattera	CNS Agents, Misc	12,026	\$ 1,759,921.86	\$ 146.34	1.01%
Adderall XR	Amphetamines	10,622	\$ 1,753,201.85	\$ 165.05	1.00%
Depakote ER	Anticonvulsants, Misc	10,472	\$ 1,665,456.19	\$ 159.04	0.95%
Total Top 25		330,614	\$80,822,595.18	\$ 244.46	46.16%




Drug Level Reporting

Figure 10: Top 10 Drugs By Total Number of Claims

Top 10 Drugs Based on Number of Claims HYDROCODONE-■ RISPERIDONE **ACETAMINOPHEN** 7% 7% 18% **LISINOPRIL** 7% CLONAZEPAM SEROQUEL 13% 8% LORAZEPAM **■ LORATADINE** 8% 12% ALPRAZOLAM ■ PREVACID 10% 10%

Figure 11: Top 10 Drugs By Total Cost of Claims



Top 10 Drugs



Conclusion

In SFY 2009, there was a growth in the number of members covered by KHPA Medical Programs, and the total expenditures. In SFY 2009, KHPA Medical Programs paid \$175,085,301 compared to \$158,877,070 in SFY 2008—an increase of over \$16 million in prescription expenditures.

Table 12 shows the total prescription cost, number of prescription claims and average members per month for the past six years.

Between SFY 2006 and SFY 2007, there was a dramatic decrease in prescription costs and prescription claims. This decrease can be primarily attributed to the shift of members into Medicare Part D.

Several of the top therapeutic classes have been top expenditures for KHPA Medical Programs over the past several years. These include antipsychotic agents, antidepressants, anticonvulsants, hemostatics, and antiretrovirals. Hemostatics and antiretrovirals represent a small number of claims, but the cost of these medications can be tremendous, with a single claim costing as much as \$150,000.

Expenditures for hemostatics have increased for KHPA Medical Programs over the past several years. The exact cause for this increase has not been determined, however one possible explanation could be members maxing out their primary insurance's lifetime benefits.

Prevacid has remained in the top drugs both by total cost of claims and total number of claims over the past several years. This is most likely due to it having been a preferred Proton Pump Inhibitor since the inception of the Preferred Drug List (PDL) in 2002. Prevacid is expected to become generically available in late 2009, which will result in a significant cost savings in this therapeutic class.

While there are several agents that appear on both the top drugs by cost of claims and total claims, the majority of the agents on these lists are used to treat mental health conditions. This has been a trend over the past several years. The KHPA Medical Programs currently have no restrictions placed on these medications due to a statutory restriction.

Table 12: Past Years' Totals

Period Covered	Prescription Claims Cost	Prescription Claims	Average Members Per Month
SFY2009	\$175,085,301	2,037,193	142,493
SFY2008	\$158,877,070	1,938,007	137,733
SFY2007*	\$153,419,466	2,395,348	294,590
SFY2006*	\$251,543,689	4,372,001	297,729
SFY2005*	\$280,443,262	4,562,932	300,435
SFY2004*	\$265,258,972	4,580,713	270,777

^{*}Annual Reports were prepared using data from the Managed Care Options.

